Unexplored treatment approaches are currently being tested, such as CAR T-cell therapy in relapsed HCL using autologous anti-CD22 CAR T-cells and against B-cell activating factor (BAFF), a ligand expressed by hairy cells [49, 50]. Here, TNFSF13B is linked to hairy cell leukemia.